Form 4: AbbVie Director Robert J. Alpern Reports Changes in Beneficial Ownership

Director Robert J. Alpern reports acquisition of stock equivalent units and updates to beneficial ownership in AbbVie Inc.

Summary

• Robert J. Alpern, a director of AbbVie Inc., filed a Form 4 with the SEC on April 2, 2024.
• The report details changes in his beneficial ownership of AbbVie securities.
• On March 31, 2024, Alpern acquired 41 stock equivalent units at a price of $182.1.
• These units were credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie.
• The balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
• The total number of stock equivalent units beneficially owned following the reported transaction is 9,408.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing detailing transactions. The director's continued investment is a mildly positive signal.

Positives

• The acquisition of stock equivalent units demonstrates the director's continued investment in AbbVie.
• Dividend reinvestment further increases the director's stake in the company.

Future Outlook

The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the transactions of a company director.

Key Dates